Quality Improvement in Molecular Testing Pathways for Metastatic Colorectal Cancer (mCRC) Grant

Quality Improvement in Molecular Testing Pathways for Metastatic Colorectal Cancer (mCRC) Grant

Status: ACTIVE
Funder: Pfizer, Inc.
Amount: US $150,000 - US $250,000
Last Updated: January 28, 2026

Summary

Overview

About Pfizer External Research & Grants Pfizer External Research & Grants (ER&G) supports independent research, education, and QI initiatives to improve patient outcomes in areas of unmet need. Competitive grants are awarded through transparent RFPs reviewed by independent expert panels. About ASCP American Society for Clinical Pathology (ASCP) is the world’s largest professional membership organization for pathologists and laboratory professionals, with more than 100,000 members. ASCP provides excellence in education, certification, and advocacy on behalf of patients and the laboratory workforce. With a portfolio of more than 900 educational activities, ASCP is the worldwide leader in providing CME/CMLE credit for the entire laboratory team. Quality Improvement in Molecular Testing Pathways for Metastatic Colorectal Cancer (mCRC) The American Society for Clinical Pathology (ASCP), in collaboration with Pfizer Inc. and with participation from the American Society of Clinical Oncology (ASCO, invites proposals for pathology-centric Quality Improvement (QI) initiatives aimed at optimizing molecular testing pathways in the management of metastatic colorectal cancer (mCRC). This grant opportunity seeks to fund sustainable projects that improve biomarker testing practices, strengthen targeted therapy selection, and support care teams in implementing patient-centered protocols. The overarching goal of this program is to advance diagnostic excellence and improve treatment decision-making for patients with mCRC.

Eligibility

We've imported the main document for this grant to give you an overview. You can learn more about this opportunity by visiting the funder's website.